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Reactivating  the  tumor  suppressor  p53 offers  an attractive  strategy  for developing  cancer
therapy.  We  recently  identiﬁed  Inauhzin  (INZ)  as  a novel  non-genotoxic  p53-activating
compound.  To  develop  INZ  into  a  clinically  applicable  anticancer  drug,  we  have  initi-
ated  preclinical  toxicity  studies.  Here,  we  report  our  study  on  determining  the  maximum
tolerated  dose  (MTD)  of INZ  analog,  Inauhzin-C  (INZ  (C)),  following  intraperitoneal  (i.p.)
administration  (Phase  A)  and  its  toxicity  following  i.p. administration  over  a period  of 5-
day dosing  plus 2-day  recovery  (Phase  B) in CD-1  mice.  The  Phase  A study  showed  that  the
MTD of INZ (C) is 200  mg/kg  for  female  and  250  mg/kg  for  male,  respectively.  The  Phase  B
study  showed  that  the  administration  of INZ  (C)  via  5-day  consecutive  i.p. injection  is  tol-
erated by female  CD-1  mice  at all dose  levels  tested  from  50  mg/kg  to 120 mg/kg  withoutMaximum tolerated dose signiﬁcant  changes  in  biochemical  and  pathological  parameters  in  the  animals.  Together,
these results  indicate  that  our previously  determined  effective  dose  of INZ  at 30–60 mg/kg
via i.p.  is quite  safe to  mice,  and  imply  that  this  compound  have  the  features  worthy  for
further  development  into  a clinically  applicable  drug.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
1. Introduction
Over 10 million cases of cancer are diagnosed world-
wide each year, leading to ∼6 million deaths. Despite
numerous scientiﬁc breakthroughs and tremendous R&D
investments in the pharmaceutical sector over the past 3
decades, cancer is still the leading cause of disease-related
mortality and awaits further advances toward improved
therapy [9]. Intensive effort has been focused on the tumor
suppressor p53 pathway because nearly all cancers show
defects in this pathway, >50% of which have mutations in
the TP53 gene itself. Aberrations in p53 or its regulators
are linked with increased resistance to current chemother-
apy and hence poor prognosis [10,11]. Thus, reactivation of
∗ Corresponding author. Tel.: +1 504 988 5293; fax: +1 504 988 1611.
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the p53 pathway in cancer has served as one prime strat-
egy for the development of novel cancer therapies. In an
attempt to take this strategy, we  discovered Inauhzin (INZ)
as a novel non-genotoxic p53 activator [1]. Our previous
studies revealed that INZ activates p53 by targeting SIRT1
in cancer cells and consequently suppresses tumor growth
[1]. SIRT1, a NAD-dependent deacetylase, deacetylates p53
and facilitates its MDM2/MDMX-mediated degradation.
Remarkably, INZ has no apparent detrimental effect on
normal cells (data not shown). Also, INZ can sensitize the
anti-cancer effect of cisplatin, doxorubicin, or Nutlin-3 (a
MDM2  inhibitor) as tested in xenograft cancer models [2,3].
Thus, this small molecule presents as a promising con-
tender for a molecule-targeted anti-cancer therapy. We
have been undertaking systematic chemical optimization
of INZ by the analysis of structure–activity relationship
(SAR) [4], and new target identiﬁcation and validation
[5]. We  found that INZ indeed induced the expression of
is is an open access article under the CC BY-NC-ND license
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tion [12]. The starting dose level (Group 1) for DRF study
has been selected based upon the ﬁndings of an efﬁcacy
study of the compound in SCID mice [1]. Detailed group
design was listed in the following table:
Group designation and dose level.
Phase A: dose range ﬁnding (DRF) study (escalating dose design)
Group No. of animals Dose level
(mg/kg/day)
Dose
concentration
(mg/mL)
Male Female
Group 1 3 3 50 5
Group 2 3 3 150a 5Q. Zhang et al. / Toxicol
53-dependent transcriptome [6], and surprisingly, we
ecently found that INZ can activate p53 by also target-
ng IMPDH2 [7], which is often highly expressed in human
ancers. These studies demonstrate that INZ possesses an
bility to target two oncoproteins, SIRT1 [1] and IMPDH2
7]. This unique ability of INZ would offer an example
or paradigm shifting from classical chemotherapy or a
ingular molecule targeted drug to dual or multi molecules-
argeted therapy for human cancers.
In order to eventually develop INZ or its derivative into a
linically applicable form, we need to assess its drugability
nd toxicity in animals. Thus, this study as reported here
as designed to determine the maximum tolerated dose
MTD) of INZ analog, INZ (C) (Compound 8 [4]), following
ntraperitoneal (i.p.) administration of ascending and/or
escending doses (Phase A) and to evaluate its toxicity fol-
owing i.p. administration over a period of 5-day dosing
lus 2-day recovery (Phase B) in CD-1 mice. The results
rom these phase studies demonstrate that INZ (C) is quite
afe within 100 mg/kg via i.p. to mice as tested, and suggest
hat this INZ derivative could serve as a lead compound for
urther preclinical analyses and development.
. Materials and methods
.1. Animals
Six to eight-week-old CD-1 mice were purchased from
hanghai SLAC Laboratory Animal Co. Ltd. Animals were
andomly assigned to dose groups based body weight
nd/or sex using Microsoft Excel program. Prior to assign-
ent to groups, the weight variation of the animals of
ach sex used did not exceed 20% of the mean weight.
fter assignment to groups the mean body weight for each
roup of each sex (both sexes for Phase A and single sex for
hase B) were not statistically different at the 5% proba-
ility level. This strain of mice has been historically used in
afety evaluation studies and is recommended by appropri-
te regulatory agencies. In addition, mice were commonly
sed in the efﬁcacy studies of cancer drugs.
Animals were group housed in solid bottom polycarbo-
ate cages (3–5 animals/cage) and provided with pelleted
ood that is pre-irradiated via Co60 by the Supplier. The
ood was provided ad libitum unless otherwise speciﬁed.
nimals were also provided with sterilized pure water ad
ibitum. No known contaminants were present in the diet
r water at levels that might interfere with this study.
nvironmental controls for the animal room were set to
aintain 20–25 ◦C, a relative humidity of 50–70%, a mini-
um of 10 air changes/h, and a 12-h light/12-h dark cycle.
he light/dark cycle might be interrupted for study-related
ctivities.
The numbers of animals, study design, and treatment of
nimals were reviewed, and approved by the ChemPartner
nstitutional Animal Care and Use Committee (IACUC). All
rocedures in this protocol are in compliance with the U.S.
epartment of Agriculture’s (USDA) Animal Welfare Act,
he Guide for the Care and Use of Laboratory Animals, the
fﬁce of Laboratory Animal Welfare and Laboratory Ani-
al  Administration ordinance issued by State Science and
echnology Committee of the Peoples Republic of Chinaorts 2 (2015) 546–554 547
(PR China), Act 2 and Laboratory Animal Administration
regulations issued by Shanghai Laboratory Animal Admin-
istration Ofﬁce, PR China.
The medical treatment necessary to prevent unac-
ceptable pain and suffering, including euthanasia, is the
responsibility of the attending Laboratory Animal Veteri-
narian. Discretionary medical treatment has been carried
out based upon consensus agreement between the Study
Director and the attending Laboratory Animal Veterinarian.
In the event of severe toxicity, in which decisions were
to be made regarding treatment or euthanasia of study
animal(s), the ChemPartner Veterinarian and the Study
Director reserve the right for subsequent action.
2.2. Test and control articles
2.2.1. Test article
The test article, INZ (C), was synthesized in our lab. The
purity of the article is greater than 99%. The synthesis route
was described in [4].
2.2.2. Control article
The control article was composed of 5% DMAC + 7%
Solutol HS15 + 88% Saline. The information of each compo-
nent of the control article was described below:
Control article Manufacturer Lot/batch no.
DMAC Sigma BCBK6482V
Solutol HS BASF 21466288KO
Saline Zhejiang Tianrui 113011102
2.3. Study design
12 naïve male and 12 naïve female CD-1 mice (for Phase
A) and 24 naïve female CD-1 mice (for Phase B) were ran-
domly assigned to the study. The animals received dose
formulation containing INZ (C) and the control article (5%
DMAC + 7% Solutol HS15 + 88% Saline) at various dosages
via i.p. injection, q.d dosing for s single dose at each dose
level (Phase A) and i.p. injection, q.d dosing for 5 consec-
utive days (Phase B). The location of the i.p. injection was
lower left abdominal quadrant. The MTD  in this study is
deﬁned as the highest dose that will be tolerated and not
produce major life threatening toxicity for the study dura-Group 3 3 3 250a 5
Group 4 3 3 200a 5
a Dose level was determined based on the result after the previous
dosing.
logy Rep548 Q. Zhang et al. / Toxico
Phase B: 5-day maximum tolerated dose study
Group No. of animals Dose level
(mg/kg/day)
Dose
concentration
(mg/mL)
Female
1 (control)a 6 0 0
2 (low) 6 30b 1.25
3 (mid) 6 60b 2.5
4 (high) 6 120b 5
a Group 1 received control article only.
b Dose level was determined based on the result of Phase A.
The following parameters and end points were evalu-
ated in this study: mortality, clinical signs, body weights,
food consumptions, hematology and serum biochemistry
parameters, post mortem evaluation included gross exam-
ination for all the animals at the terminal necropsy and
histopathological examination of major organs in the con-
trol and high dose groups.
Hematology and clinical chemistry were tested at ter-
mination on Day 7 for each dose level. Animals were fasted
for ∼4 h for scheduled blood collections.
The necropsy included an examination of the external
features of the carcass; external body oriﬁces; the abdomi-
nal, thoracic, and cranial cavities; organs/tissues deﬁned in
Suppl. Table 5 from 3 surviving animals were examined for
morphological evaluations.
2.4. Termination
2.4.1. Unscheduled sacriﬁces and deaths
Animals exhibiting signs of acute pain or distress, which
were unable to eat, walk, groom normally, or moribund, or
have other signs of severe systemic toxicity were eutha-
nized immediately.
Animals eventually found dead were refrigerated, if
necessary, and necropsied at the earliest possible time. Ani-
mals sacriﬁced at an unscheduled interval were weighed,
anesthetized and necropsied, and discarded after gross
observations of tissues as speciﬁed in Suppl Table 5.
2.4.2. Scheduled sacriﬁce
2.4.2.1. Terminal sacriﬁce. Phase A: on Day 10 all surviv-
ing animals were euthanized and disposed of without
necropsy.
Phase B: on Day 8, all surviving animals were fasted ∼4 h
before termination, and then anesthetized with Phenobar-
bital, exsanguinated, and necropsied.
2.4.2.2. Postmortem procedures. Phase A: none.
Phase B: the necropsy includes an examination of the
external features of the carcass; external body oriﬁces; the
abdominal, thoracic, and cranial cavities; organs/tissues
deﬁned in Table 6 from 3 surviving animals were subjected
to morphological evaluations.
2.5. Statistical evaluationNo statistical evaluation was done for data collected
from Phase A study. One-way analysis of variance (ANOVA)
was used (if applicable) to analyze continuous clinicalorts 2 (2015) 546–554
pathology values and body weight data (Phase B only).
If the ANOVA were signiﬁcant, Dunnett’s t-test would be
used for pairwise comparisons between treated and con-
trol groups. Group comparisons (Groups 2–4 versus Group
1) were evaluated at the 5.0%, two-tailed probability level.
3. Results
3.1. Phase A
In order to further develop INZ into a clinically appli-
cable form, we started to perform a series of preclinical
animal studies. Because our recent structure–activity rela-
tionship (SAR) study revealed that INZ (C) (Compound 8
[4]) is more effective than INZ in p53 activation [4] and bet-
ter pharmacokinetics proﬁle (data not shown), we  decided
to use this INZ analog as our lead compound for Phases A
and B studies here. First, we  determined the lethal dose or
maximum tolerated dose of this compound by employing
CD-1 mice. As shown in Table 1, mortality was  observed
in females (1 was found dead on Day 2 and 2 were found
dead on Day 3) at 250 mg/kg only during this study phase
(Suppl. Tables 1-1 and 1-2). Abnormal clinical signs, such
as piloerection, decreased motor activity, discharge around
eye(s), cold to touch, etc. were observed at 150 mg/kg and
above for both sexes (Suppl. Tables 2-1 and 2-2). Also, a
trend of increasing in mean body weight was observed
at 50 mg/kg for both sexes, while a dose-dependent trend
of mean body weight loss was  observed at 150, 200 and
250 mg/kg for both sexes by comparing the mean body
weight on Day 1 and 4 for all the 4 dose levels (data not
shown).
Unscheduled necropsy was conducted immediately
after the animals were found dead (Suppl. Tables 3-1 and
3-2). Decreased size of spleen and liquid with large volume
in the thoracic cavity was  noticed. Other observations such
as duodenum autolysis, liver discoloration were consid-
ered as degeneration of animal body post mortem; white
substance in the abdominal cavity was  considered as drug
residue precipitated from the dose formulation after dos-
ing. No evidence of dose accident was  noticed.
Furthermore, scheduled necropsy was  conducted in
all the surviving animals at termination of each dose.
White substance was  observed on the surface of liver,
spleen and diaphragm in the surviving animals from groups
of 200 mg/kg and above, which was considered as drug
residue precipitated from the dose formulation after dos-
ing.
Taken together, the results obtained from the Phase
A study show that the maximum tolerated dose of INZ
(C) is 200 mg/kg for female and >250 mg/kg for male,
respectively, based on the mortality and the clinical signs.
Therefore, female mice are more sensitive than male mice
to INZ (C) under the current study condition and were used
in Phase B study as described below.
3.2. Phase BNext, we  used female mice for Phase B study here with
different doses of INZ (C) from 30 mg/kg to 120 mg/kg per
day via i.p. for ﬁve days. No mortality was  observed to all the
Q. Zhang et al. / Toxicology Reports 2 (2015) 546–554 549
Table  1
Individual daily food consumption, female, Phase B.
Group no. Food weight (g) Total food consumption (g) Mean individual food
consumption (g)
Day 1 Day 5 Day 1–Day 5
Control
0 mg/kg
201.1 141.53 59.57 1.99
Low/♀
30 mg/kg
205.55 149.94 55.61 1.85
Mid/♀
60 mg/kg
204.21 141 63.21 2.11
High/♀
120 mg/kg
202.06 143.93 
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Fig. 1. Mean body weight–time proﬁle of INZ-C following by 5-day con-
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tested, although there were some dose-dependent changesecutive intraperitoneal injection at 30, 60 and 120 mg/kg and a 2-day
ecovery phase in female CD-1 mice (N = 6).
ested animals at all dose levels during the study phase. No
bnormal clinical observations were noticed as well (Suppl.
ables 1-1 and 1-2 and data not shown). In addition, we
ave performed the following examinations and analyses,
nd found no apparent toxic effects of this compound on
he animals as follows.
First, we found that the mean body weight of all the 3
reatment groups are comparable with the control group
nd ﬂuctuated from day to day without clear trend of
ncreasing or decreasing (Fig. 1). No statistic difference in
ody weight and body weight gain among the groups was
etected by One-way ANOVA. Therefore, no treatment-
elated effects on body weight could be detected.
Also, the mean individual food consumption of all the 3
reatment groups was comparable with the control group
nd appeared not to be dose-dependent. Therefore, no
reatment-related effects on mean individual food con-
umption could be detected either (Table 1).
Grossly examining the organs of the animals
evealed some changes. For instance, although discol-
ration/enlargement of spleen and thin duodenum wall
ere observed sporadically in low and mid  dose groups
Suppl. Table 4), in the high dose group, edge of liver
obes-blunt (6/6), spleen enlargement (4/6), adhesion
6/6) of organs (liver, spleen, stomach, kidney) with each
ther were extensively observed. Also white substance
as observed extensively in the abdominal cavity in the
igh dose group, but not in low and mid  dose groups,
hich was considered as drug residue. Therefore, the
bnormal gross examination ﬁndings in the high dose
roup were considered non-systemic and correlated with
he presentation of the drug residue, which probably was58.13 1.94
caused by the irritation of the INZ (C) formulations with
the multiple i.p. injection.
Hematological analysis was also conducted. Dose-
dependent increasing in absolute/relative neutrophil
(1.2–1.6 (absolute) folds and 1.2–1.7 (relative) folds versus
control group) and basophil (1.5–2.5 (absolute) folds and
1.0–1.9 (relative) folds versus control group) was noticed
in treatment groups compared with the control group
(Table 2). Also trend of increasing of relative reticulocyte
(1.1–1.3 folds versus control group) was observed, which
was considered as isolated incidence due to lack of dose-
dependency and correlation with the changes of other
erythrocytic parameters.
Biochemical analysis of animal blood samples showed
the increase in aspartate aminotransferase (AST) level in
120 mg/kg group only. However, it could not be concluded
as dose-related due to absence of dose-dependency in
all other dose levels (Table 3). The elevation of alanine
transarninase (ALT) in 120 mg/kg group was due to an
abnormal ALT level in a single animal (24004). Therefore,
it was considered as an isolated incidence. DBIL and ALP
were reduced in a dose dependent and statistically signiﬁ-
cant manner (P < 0.05 and P < 0.01, respectively), suggesting
that INZ might cause liver toxicity that is associated with
the elevation of DBIL and ALP levels.
Histopathology assessment was conducted in control
and high dose groups only (Suppl. Table 5, Figs. 2–4).
Abnormal morphological changes were observed in all the
brains (hemorrhage) and kidneys (cortex renal tubular
epithelial cells undergoing degeneration), and sporadically
in livers (inﬁltration of focal inﬂammatory cells mainly
macrophage) of both control and high dose groups. There-
fore, they were not considered as drug-related, probably
were artifacts. We  observed the hepatic capsule thickening
within inﬂammatory cell inﬁltration mainly in neutrophils
at doses of INZ higher than 50 mg/kg, which might be
related to the increase of DBIL and ALP levels (Table 3, Fig. 3
and Suppl. Table 5).
In summary of the Phase B study, based on the absence
of clinical ﬁndings in all animals, minimal body weight
and food consumption changes, it was concluded that
administration of INZ (C) via 5-day consecutive intraperi-
toneal injection is tolerated by female CD-1 mice under
current study condition of Phase B at all dose levelsin hematology parameters (absolute/relative neutrophil
and basophil counts), which were considered tolerable.
Gross ﬁndings observed in the terminal necropsy were
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Table 2
Hematology, female, Phase B.
Group no. Animal no. WBC  (×109/L) RBC (×1012/L) HGB (g/L) HCT (%) MCV  (fL) MCH  (pg) MCHC (g/L) PLT (×109/L) RET (%) RET (×109 cells/L)
Control/♀ 21001 4.2 10.19 147 49 48.1 14.4 300 1094 5.32 541.9
0  mg/kg 21002 3.56 10.2 149 49.5 48.6 14.6 300 797 5.55 565.8
21003  3.18 10.03 146 48.2 48 14.6 304 742 6.27 629.4
Mean  3.65 10.14 147 48.9 48.2 14.5 301 878 5.71 579
SD  0.52 0.1 2 0.7 0.3 0.1 2 189 0.5 45.2
Change  (fold) 1 1 1 1 1 1 1 1 1 1
Inauhzin-C 22001 4.01 8.96 136 43.9 49 15.2 310 1139 6.02 539.1
Low/♀ 22002 4.23 9.92 143 47.8 48.2 14.5 300 955 5.07 503.2
30  mg/kg 22003 3.65 9.07 132 43.7 48.2 14.5 301 675 7.34 665.8
Mean  3.96 9.32 137 45.1 48.5 14.7 304 923 6.14 569.4
SD  0.29 0.53 6 2.3 0.5 0.4 6 234 1.14 85.4
Change  (fold) 1.1 0.9 0.9 0.9 1 1 1 1.1 1.1 1
Inauhzin-C 23001 3.19 9.35 141 46.7 50 15.1 302 665 6.11 570.9
Mid/♀ 23002 5.23 8.97 140 46.8 52.2 15.6 300 1182 10.08 904.3
60  mg/kg 23003 3.26 8.97 134 44.7 49.8 15 301 1235 6.92 621.4
Mean  3.89 9.1 138 46.1 50.7 15.2 301 1027 7.7 698.9
SD  1.16 0.22 4 1.2 1.3 0.3 1 315 2.1 179.7
Change  (fold) 1.1 0.9 0.9 0.9 1.1 1 1 1.2 1.3 1.2
Inauhzin-C 24001 2.15 8.84 133 42.9 48.5 15 309 776 6.57 580.8
High/♀ 24002 6.28 8.69 131 43.5 50 15.1 302 1164 7.41 649.5
120  mg/kg 24003 2.32 9.61 146 48.6 50.5 15.2 302 1062 7.54 724.1
Mean  3.58 9.05 137 45 49.7 15.1 304 1001 7.17 651.5
SD  2.34 0.49 8 3.1 1 0.1 4 201 0.53 71.7
Change  (fold) 1 0.9 0.9 0.9 1 1 1 1.1 1.3 1.1
Group  no. Animal no. Abs neuts
(×109 cells/L)
%NEUT (%) Abs lymphs
(×109 cells/L)
%LYM (%) Abs monos
(×109 cells/L)
%MONO (%) Abs eos
(×109 cells/L)
%EOS (%) Abs basos
(×109 cells/L)
%BASO (%)
Control/♀ 21001 1.01 24.2 2.93 69.9 0.13 3.1 0.08 1.9 0.01 0.2
0  mg/kg 21002 1.12 31.4 2.27 63.8 0.07 1.9 0.07 2 0.01 0.4
21003  0.86 26.9 2.06 64.9 0.07 2.1 0.17 5.3 0 0.1
Mean  1 27.5 2.42 66.2 0.09 2.37 0.11 3.07 0.01 0.23
SD  0.13 3.6 0.45 3.3 0.03 0.64 0.06 1.93 0.01 0.15
Change (fold) 1 1 1 1 1 1 1 1 1 1
Inauhzin-C 22001 1.19 29.6 2.6 64.9 0.12 2.9 0.07 1.8 0.01 0.1
Low/♀ 22002 1.06 25 2.85 67.3 0.18 4.1 0.12 2.7 0.01 0.2
Q. Zhang et al. / Toxicology Rep
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considered the irritation of INZ (C) formulations with the
multiple i.p. injection. Findings observed at microscopic
examination of tissues from control and high dose groups
were not considered as drug-related due to presenting in
both groups. Hence, our compound INZ (C) is quite safe to
this strain of mice within the 120 mg/kg dose range via i.p.
administration.
4. Discussion
In this study, a dose range-ﬁnding (ORF) study has been
performed to assess the toxicological proﬁle of INZ analog,
INZ (C) (Compound 8 [4]), following a single dose adminis-
tration in CD-1 mice in Phase A study. The established MTD
of 200 mg/kg for female and 250 mg/kg for male, respec-
tively, offers the rationale for selecting the doses for a 5-day
toxicity study with female mice in Phase B study. The Phase
B study has been performed at 4 dose levels (0 = control, 30,
60 and 120 mg/kg) of INZ (C) administered daily by i.p. for
5 days, and different parameters, such as mortality, body
weight, food consumption, clinical pathology and gross
pathology, were examined during and/or at termination of
the study. Major organs, such as brain, lung, liver, aderanal
gland, kidney, spleen, heart, ovary and uterus/prostate and
testis were collected for possible histopathology evalua-
tion. The biochemical assays were performed to measure
the liver and kidney toxicity of INZ (C). For the Phase
A study, clinical ﬁndings and lethality were observed in
females at 250 mg/kg. For the Phase B study, it is con-
cluded that administration of INZ (C) could be tolerated
by 5-day consecutive dosing via intraperitoneal injection
in female CD-1 mice under current study condition as no
changes were observed in mean body weight, body weight
gain and food consumption, although ﬁndings were noticed
in gross/microscopic examination and part of the clinical
pathology parameters. These toxicity studies demonstrate
that INZ (C) is a quite safe compound within one week of
treatment at the dose of less than 120 mg/kg via i.p.
Translating a promising SIRT1 and IMPDH2 dual
inhibitor with excellent in vitro properties into an anti-
cancer drug requires that the inhibitor has excellent
pharmacological properties and is nontoxic or less to toxic
to normal tissues. We have proved the efﬁcacy of INZ in
several preclinical models of lung and colon cancer [1,2].
The ﬁrst example is the xenograft tumors derived from
aggressive H460 cells in severe combined immunodeﬁ-
ciency (SCID) mice. At the dose of 30 mg/kg via i.p. injection
once every other day (Q.O.D.) for 3 weeks, INZ signiﬁcantly
reduced the average tumor weight at the end of the exper-
iment by nearly 40%. Moreover, INZ-treated H460 tumors
displayed elevated p53 compared to the vehicle-treated
tumors by immunoblotting. In another xenograft tumor
model, INZ was very effective in inhibition of HCT116
tumor growth as it signiﬁcantly reduced tumor growth and
weight by ∼70% after 30 mg/kg via i.p. once per day. In
addition, we  demonstrated that INZ and Nutlin-3 syner-
gistically induces p53 and suppresses HCT116 xenograft
tumor growth [8]. At the dose of 15 mg/kg of INZ and
150 mg/kg of Nutlin-3, each of the compounds could indi-
vidually reduce the average tumor volume by less than 20%
after treatment for 21 days. However, when combining the
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Table 3
Serum chemistry, female, Phase B.
Group no. Animal no. ALT (U/L) AST (U/L) TBIL (mol/L) DBILa (mol/L) ALP (U/L)a Urea (mmol/L) CREA (mol/L)
Control/♀ 21004 35.1 81.8 1.9 1.1 169 5.2 12.5
0  mg/kg 21005 35.5 108 1.3 0.7 141.9 5.9 12.6
21006 35.2 78.3 1.9 1.2 172.6 5.9 13.5
Mean 35.3 89.4 1.7 1 161.2 5.7 12.9
SD  0.2 16.2 0.3 0.3 16.8 0.4 0.6
Change (fold) 1 1 1 1 1 1 1
Inauhzin-C 22004 24.9 75.9 1.2 0.8 133.9 5 13.2
Low/♀ 22005 50.1 143.1 1 0.7 151.1 6 13.3
30  mg/kg 22006 24.1 69.5 0.9 0.6 140.1 6.9 14
Mean 33 96.2 1 0.7 141.7 6 13.5
SD  14.8 40.8 0.2 0.1 8.7 1 0.4
Change (fold) 0.9 1.1 0.6 0.7 0.9 1.1 1
Inauhzin-C 23004 28 66.2 1.4 0.7 97.1 6.7 10.9
Mid/♀ 23005 32.4 98.3 0.8 0.5 115.9 5.9 12.8
60  mg/kg 23006 24.1 67.9 0.9 0.5 153.2 6.7 16
Mean 28.2 77.5 1 0.6 122.1 6.4 13.2
SD  4.2 18.1 0.3 0.1 28.6 0.5 2.6
Change (fold) 0.8 0.9 0.6 0.6 0.8 1.1 1
Inauhzin-C 24004 101 119.8 0.9 0.5 76 3.8 9.8
High/♀ 24005 37.2 110 1 0.3 58.2 5 14.8
120  mg/kg 24006 37.1 116.7 1.3 0.6 73.4 5.1 13.5
Mean 58.4 115.5 1.1 0.5 69.2 4.6 12.7
SD  36.9 5 0.2 0.2 9.6 0.7 2.6
Change (fold) 1.7 1.3 0.6 0.5 0.4 0.8 1
a Dose dependent, and statistically signiﬁcant P < 0.05.
Fig. 2. Some representative images of morphologic changes in brain.
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wo treatments at the same doses, the ﬁnal average volume
f tumors was signiﬁcantly decreased by 60%. Recently,
e have further tested the combined anti-tumor effects
f INZ and current ﬁrst-line chemotherapeutic drugs, such
s cisplatin, in the H460 xenograft tumor model. As a
esult, we found the enhanced growth suppression of
enografted lung cancer with combination of INZ and cis-
latin at lower doses [3]. All these results demonstrate
hat INZ cooperates with other drugs that have different
n vivo mechanisms of action, such as the MDM2  inhibitor
utlin-3 or the DNA-damaging chemotherapeutic drug
isplatin, efﬁciently activate p53 and suppress xenograft
umor growth in animals. In line with the results in this
eport here, the effective dose of INZ has been shown to
isplay little toxicity to the animals used in those previous
tudies [1]. Taken together, all of these studies including
his report demonstrate that our previously reported effec-
ive doses of 30–60 mg/kg via i.p. are in the safe range to
he small rodent animals.
Fig. 4. Some representative images of morprphologic changes in mouse liver.
Our biochemical toxicity studies, such as BUN (blood
urea nitrogen), ALT (alanine aminotransferase), AST (aspar-
tate aminotransferase), ALP (alkaline phosphatase), and
total bilirubin (TBIL) biochemical assays, and histopatho-
logy assessments showed that INZ (C) does not appear to
cause apparent hepatotoxic and kidney toxic in mice at all
the dose levels tested in Phase B (Tables 2 and 3, Figs. 2–4
and Suppl. Table 5). In addition, through the whole Phase B
toxicity experiment, both groups of animals, control and
INZ (C)-treated groups, were healthy without apparent
changes in their behavior, food appetite and body weight.
These results, therefore, are in line with expectations that
INZ (C) is a potent and non-toxic anti-cancer agent, and
provide solid evidence for the further evaluation of INZ as
a potential promising therapy in cancers.Signiﬁcant difference in the toxicity of INZ at
250 mg/kg was  found between different sexes after 2 days
(Suppl. Table 1). The INZ(C)-treated female mice showed
many abnormalities, including decreased motor activity,
hologic changes in mouse kidney.
logy Rep
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piloerection, discharge both eyes, eye(s) partly closed,
cold to touch and deep respiration. In contrast, no such
abnormalities were observed in male mice and they
became tolerated to the treatment. Since no toxicities
were found besides the liver toxicity associated with
the dose dependence of DBIL and ALT levels in Phase B
studies (Tables 2 and 3 and Figs. 2–4), the sex-related
metabolism in liver microsomes may  result in the sex
differences in INZ(C) induced liver toxicity. We  will inves-
tigate the metabolisms from both sexes in the liver
microsomes by HPLC/MS in our future studies, and deter-
mine which cytochrome P450s (CYPs) responsible for
INZ(C) metabolism is male-speciﬁc or predominant.
For animal studies, the i.p. route is a practical and
alternative route compared to other conventional drug
delivery routes. It is most useful for substances that are
degraded in gastrointestinal (GI) tract and insufﬁciently
absorbed. Bioavailability of i.p. is almost similar to intra-
venous (i.v.), and greater than oral routes. In addition,
substances are administered during clinical trials, by sev-
eral routes, depending on the tumor type. Most recently,
the i.p. route has been used for chemotherapy in patients
with intra abdominal malignancies, i.e. gynecological and
gastrointestinal cancers, and has shown very promising
results. In patients with peritoneal surface malignancies,
such as ovary cancers, chemotherapy via i.p. has resulted
in satisfactory results [9].
INZ (C) has a short half-life in liver microsomes (date
not shown) and does not have desired oral bioavailability.
Thus, the oral route is not suitable for INZ (C) in the toxic-
ity studies. Because of these caveats, we have been trying
to improve the solubility and the metabolic stability of INZ
(C) by optimizing the structure and developing oral for-
mulations. Moreover, we are testing INZ (C) in a variety
of tumors in orthotopic cancer murine models, including
colon cancers and ovary cancers. The eventual therapeutic
dosing route for INZ or its optimized derivative will depend
on its physiochemical property and which tumors it affects
mostly.
Tests and abbreviation.
Hematology
Red blood cell (erythrocyte)
count (RBC)
Platelet count (PLT)
Hemoglobin White blood cell (leukocyte)
count (WBC)
Hematocrit
Mean corpuscular volume
(MCV)
Mean corpuscular hemoglobin
(MCH)
Differential blood cell count
Mean corpuscular hemoglobin
concentration (MCHC)
Reticulocyte count (RETIC)
Clinical chemistry
Blood urea nitrogen (BUN) Alanine aminotransferase
(ALT)
Creatinine (CREA) Alkaline phosphatase (ALP)
Bilirubin (BIL) Aspartate aminotransferase
(AST)orts 2 (2015) 546–554
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